chitosan has been researched along with rivastigmine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, J; Baboota, S; Fazil, M; Haque, S; Kumar, M; Md, S; Sahni, JK | 1 |
| Muthu, MS; Samanta, MK; Vinothapooshan, G; Wilson, B | 1 |
| Mishra, DN; Nagpal, K; Singh, SK | 1 |
| Khunt, D; Misra, M; Padh, H; Shah, B | 1 |
| Afzal, O; Al-Abbasi, FA; Almalki, WH; Alrobaian, M; Alshehri, S; Altamimi, ASA; Beg, S; Gao, Y; Ibrahim, IAA; Katouah, HA; Kazmi, I; Panda, SK; Rahman, M; Soni, K | 1 |
5 other study(ies) available for chitosan and rivastigmine
| Article | Year |
|---|---|
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Topics: Administration, Intranasal; Animals; Biological Availability; Blood-Brain Barrier; Brain; Chitosan; Drug Carriers; Female; Male; Microscopy, Confocal; Nanoparticles; Neuroprotective Agents; Particle Size; Permeability; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine | 2012 |
Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chitosan; Cholinesterase Inhibitors; Drug Carriers; Drug Stability; Nanoparticles; Particle Size; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Solubility; Tissue Distribution | 2011 |
Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety.
Topics: Amnesia; Animals; Behavior, Animal; Body Weight; Brain; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Evaluation, Preclinical; Factor Analysis, Statistical; Male; Maze Learning; Memory; Mice; Nanoparticles; Neuroprotective Agents; Phenylcarbamates; Polysorbates; Rats; Rivastigmine; Scopolamine; Treatment Outcome | 2013 |
Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Topics: Administration, Intranasal; Adsorption; Alzheimer Disease; Animals; Biological Availability; Biological Transport; Blood-Brain Barrier; Brain; Chitosan; Cholinesterase Inhibitors; Cholinesterases; Chromatography, High Pressure Liquid; Drug Compounding; Drug Delivery Systems; Drug Liberation; Emulsions; Humans; Isotope Labeling; Nasal Mucosa; Rats; Rats, Sprague-Dawley; Rivastigmine; Solubility; Tissue Distribution | 2018 |
Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer's disease.
Topics: Adhesiveness; Administration, Intranasal; Alzheimer Disease; Animals; Brain; Cellulose; Chitosan; Cholinesterase Inhibitors; Drug Compounding; Drug Delivery Systems; Drug Liberation; Goats; In Vitro Techniques; Lectins; Microspheres; Nasal Mucosa; Particle Size; Rivastigmine | 2021 |